Let's Uncover a Successful Pharmaceutical Pitch Deck [The Healx Teardown]

Here's an uncomfortable truth about pharmaceutical pitch decks: most of them are bad. Not technically bad. Bad in the way a wedding speech from someone who didn't prepare is bad. Forgettable. Polite. Crammed with stock photos of handshakes and words like "synergy" that no human has ever spoken out loud without irony.

And then, occasionally, you stumble across a deck that does the opposite. A deck that takes a topic most people would politely nod at and walk away from, and instead grabs the room by the collar.

The Healx Deck.

Fifteen slides. A subject most investors don't pretend to understand. A market that, by definition, is fragmented into thousands of small patient populations. And they walked out with one of the largest AI-for-drug-discovery rounds in Europe.

So, let's pull this thing apart, slide by slide, and figure out what they actually did right.

Ink Narrates is a Pitch Deck Design Agency

To date, our work has helped startups & companies raise over $250Mn in funding & secure critical business wins.

Here's the Healx Pitch Deck for Your Reference...

Healx is in the business of finding new uses for existing drugs to treat rare diseases.

There are roughly 7,000 known rare diseases. About 95% of them have no approved treatment. The traditional pharma model (spend a decade and a couple of billion dollars to bring one molecule to market) doesn't work when the addressable patient population is a few thousand people worldwide. So the entire category is, mathematically speaking, ignored.

Healx's pitch is that AI changes the math.

Their platform, Healnet, mines biomedical data to surface drug-condition matches that humans would never find in a reasonable timeframe. It is a deep-tech story dressed in a healthcare mission. Which is harder to pitch than it sounds, because you have to make two audiences happy at once: investors who want returns, and investors who want to feel like they're not soulless.

That tension shows up in the deck.

And the way Healx resolves it is, frankly, the most interesting thing about the document.

Slide-by-Slide Breakdown of this Pharmaceutical Pitch Deck

Slide 1 — The Cover

A clean cover slide with the Healx logo and the tagline framing them as patient-inspired and AI-powered. No hero image, no clever metaphor, no quote from a Nobel laureate. Just the name and what they do.

This is the kind of restraint people preach about and almost never practice. The cover slide does one job: tell the investor what's about to happen. Healx does that and gets out of the way. There's a lesson in here for the founders who spend three hours picking a cover image. Nobody is funding you because of your cover slide. They are, however, occasionally not funding you because of it.

Slide 2 — The Mission

Here is where Healx starts doing something interesting. Instead of opening with a market size graph or a chart that climbs to the right, they open with a statement of purpose. They tell you, in plain language, that they exist to treat the untreatable.

You can dismiss this as soft. But notice what it does. It frames everything that follows. Every metric, every team bio, every product screenshot now reads as evidence in service of a mission, not a list of features in search of a story. People don't write checks for features. They write checks for stories.

Slide 3 — The Problem

This is the slide most decks botch, and Healx nails it by stacking two problems on top of each other.

Problem one: drug discovery is slow, expensive, and failure-prone. The industry numbers are brutal — ten to fifteen years, two billion dollars per drug, a failure rate that would get you fired from any other profession.

Problem two: 400 million people worldwide live with a rare disease, and 95% of those diseases have no treatment at all.

The genius of stacking them this way is that one problem is industrial, the other is human. Investors get both halves of their brain activated. The analytical half sees a broken multi-billion-dollar process. The other half sees a child without a diagnosis. You can't argue with either.

Slide 4 — Why Now

Often skipped, often the most important slide in any deck. Healx answers it with the convergence story: biomedical data has exploded, machine learning has matured, and rare-disease patient advocacy groups have organized themselves into actual buyers and partners. None of these existed at scale ten years earlier.

The unspoken message: if you don't fund us now, someone else builds this in eighteen months. Urgency without melodrama.

Slide 5 — The Solution

Healx introduces Healnet, their AI platform, and they do it without trying to teach you machine learning. They describe the platform in terms of what it produces — drug-disease matches at a fraction of the cost and time — rather than how it works under the hood.

This is the move. When your tech is genuinely complex, the temptation is to prove how smart you are. Resist it. Investors are not buying your algorithms. They are buying the consequence of your algorithms.

Slide 6 — The Product / Pipeline

Now they show the pipeline. Specific rare diseases being targeted. Stages of progress. Therapeutic areas. This is where the abstract solution becomes concrete: we don't just have a platform, we have a pipeline of programs in motion.

A pipeline slide does something subtle. It converts "we could" into "we are." That single shift is worth millions in valuation.

Slide 7 — Traction & Validation

Here Healx leans on the metric that became the headline of the entire deck: a roughly tenfold lower attrition rate than industry standard. They don't have classic revenue traction in the SaaS sense, so they substitute a scientific KPI that means something to the people in the room.

Lesson worth tattooing on a wall somewhere: if you don't have the traction metric investors expect, find a metric they didn't know to ask for, and make it impossible to ignore.

Slide 8 — Partnerships

This is the credibility slide. Patient foundations, pharma partners, academic institutions. Each logo is a vote of confidence from someone who, in theory, has no reason to publicly endorse a small AI company unless the AI company actually works.

Logos by themselves are wallpaper. Logos paired with what the partnership produced are leverage. Healx threads that needle.

Slide 9 — Business Model

A slide that calmly explains how the company makes money: licensing deals, milestone payments, royalties, partnership revenue. Not flashy. Not particularly novel. But credible, and that's the point. Investors in deep tech don't want a reinvention of monetization. They want to know there is a path from science to dollars that resembles paths they've seen before.

Slide 10 — Market Opportunity

Healx avoids the classic mistake of slapping a $1 trillion total addressable market figure on the wall and pretending it's real. They frame the market by the population they serve and the unmet need within it. 400 million patients. Thousands of conditions. A combined drug-discovery spend running into the hundreds of billions.

The numbers are big enough to matter without being so big they invite eye-rolling. That balance is harder than it looks.

Slide 11 — Competition

A two-axis map showing where they sit relative to other players in AI drug discovery and rare disease. Their corner of the map is conveniently uncrowded.

Yes, every competition slide ends up with the company in the empty quadrant. Investors know this. The point is to show that you've thought rigorously about who else is in the space and why your wedge is defensible. Healx does that without pretending no competitors exist.

Slide 12 — The Team

This is where deep-tech companies live or die. Healx shows a roster heavy with PhDs, former pharma executives, and academic credibility. The implicit message: this isn't two kids who watched a YouTube video about TensorFlow. This is a team that has spent careers inside drug discovery and decided to attack it from a new angle.

For technical founders, this is the slide to overinvest in. The team page de-risks the entire pitch. A weak team slide undoes every brilliant slide before it.

Slide 13 — Milestones & Roadmap

A clean timeline showing what they've done and what's next. Programs entering clinical trials. Platform expansions. Partnership targets.

The unsexy truth about roadmap slides is that they're a test of judgment. Promise too much and you look naive. Promise too little and you look unambitious. Healx threads it with milestones that are big enough to be exciting and specific enough to be measurable.

Slide 14 — The Ask

The raise amount. What the money will be used for. Allocation across pipeline, platform, and team. No coyness about it. Investors aren't reading the deck for entertainment. They want to know what you want and what they get.

Slide 15 — Closing / Contact

A return to the mission. Contact info. The final image is a reminder that behind every line item in the pipeline is a patient waiting.

Bookending the deck this way — mission at the start, mission at the end — is what makes the whole thing feel coherent rather than like a stack of unrelated slides held together with staples.

What Healx (The Pharma Pitch Deck) Got Right

Strip away the specifics and three patterns emerge.

They picked a hard problem and refused to soften it.

The deck doesn't try to make rare-disease drug discovery sound easier than it is. It leans into the difficulty, because the difficulty is the moat. If the problem were easy, the opportunity would already be gone.

They translated complexity into consequence.

Every technical claim in the deck ends in a number an investor can hold onto. The platform exists, but the only thing that matters is what the platform produces: faster timelines, lower attrition, more programs per dollar.

They gave the investor both halves of the decision.

The analytical case is airtight. The emotional case is unavoidable. Most decks lean entirely into one or the other. The good ones do both, deliberately.

How to Engage Our Agency for Your Pharma/Biotech Pitch Deck

The process is extremely easy & transparent. Just click the "Start Your Project" button to calculate your exact pricing based on slide count, complete the payment, and a Creative Director will get in touch with you within 12 hours.